Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)

The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rosacea Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Investigator site 1

Hamilton, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM according to package insert

Treatment and study plan

Mirvaso® / Onreltea TM

Other

Primary outcomes

Satisfaction Among Patients to Whom Mirvaso®/OnrelteaTM is Prescribed Question

Time frame: Week 4

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Collaborators

Chiltern International Inc.

Registry information

Official study title

Mirvaso® Utilisation and Patient Satisfaction Evaluation

Acronym: MUSE

Important dates

Study start: 2015
Primary completion: 2016
Study completion: 2016
First posted: Dec 22, 2015
Registry last updated: May 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed